Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals — Investor Presentation (December 2021)

28 slides from Bellicum Pharmaceuticals's investor presentation, Dec 6, 2021

  1. Slide 1: Building a powerful new future in cellular IO

    Exhibit 99.1 Investor Presentation Building a powerful new future in cellular IO December 2021

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ platform, our CaspaCIDe safety switch, and related technologies; our product candidates inc

  3. Slide 3: Building a Powerful New Future in Cellular IO

    Building a Powerful New Future in Cellular IO Our GoCAR platform is engineered to break through the limitations of current cell therapies Persistence Proliferation Enhances effector cell Boosts effector cell functional persistence by proliferation and extends resisting exhaustion and survival, poten

  4. Slide 4: Product Pipeline

    Product Pipeline Establishing the clinical value of GoCAR-T in solid tumors to propel cellular IO forward Clinical Product Candidate Discovery IND-Enabling Proof-of-Concept BPX-601 Castration-Resistant Prostate Cancer PSCA GoCAR-T PSCA+ Pancreatic Cancer BPX-603 HER2+ Solid Tumors HER2 GoCAR-T (Dual

  5. Slide 5: Technology Overview

    Technology Overview > Bellicum 5

  6. Slide 6: GoCAR: Differentiated Technology Platform

    GoCAR: Differentiated Technology Platform Current Generation CAR Technology Next Generation GoCAR Technology Rimiducid Inducible MyD88/CD40 ”iMC” 6

  7. Slide 7: GoCAR Proliferation: Superior Expansion and Resistance to T Cell Exhaustion

    GoCAR Proliferation: Superior Expansion and Resistance to T Cell Exhaustion iMC activation limits T cell dysfunction in repeat tumor stimulation exhaustion assay T cell IL-2 production T cell expansion HER2+ tumor 100 100000 cells BPX-603 + Rim 10000 BPX-603 + Rim NT NT 1000 Repeat HER2.z HER2.z 10

  8. Slide 8: GoCAR Persistence: Resistance to Immune Suppressive TME

    GoCAR Persistence: Resistance to Immune Suppressive TME iMC overrides common inhibitory molecules in the tumor microenvironment TGF-b PD-L1 Inhibitory TME 140 35 BPX-601 + Rim BPX-601 + Rim 120 30 M2 MF 25 100 PGE MDSC 2 80 BPX-601 20 BPX-601 BPX-601 + PD-L1 BPX-601 + TGF-b 60 15 PD-L1 BPX-601 + TGF

  9. Slide 9: CaspaCIDe Safety Switch

    CaspaCIDe Safety Switch Inducible apoptosis to mitigate cell therapy-mediated adverse events Potential Applications • Controlling toxicity associated with cell therapies • Cytokine Release Syndrome • ICANS • Targeting antigens with known or potential high-risk side effects • Developing next-generati

  10. Slide 10: Clinical Experience with CaspaCIDe (iC9)

    Clinical Experience with CaspaCIDe (iC9) 1 2 Experience from Rivo-cel Program CAR-T Case Report from University of North Carolina 24 pediatric haplo-HSCT patients experienced advanced 26-year-old female with relapsed B-ALL received CD19.iC9 or steroid-refractory GvHD from iC9-containing allogeneic C

  11. Slide 11: Dual-Switch GoCAR-T

    Dual-Switch GoCAR-T A controllable system to manage CAR-T proliferation, persistence, and safety Lead Program: BPX-603 (HER2) 11

  12. Slide 12: BPX-601 PSCA GoCAR-T

    BPX-601 PSCA GoCAR-T 12

  13. Slide 13: BPX-601 GoCAR-T Targets Solid Tumors Expressing PSCA

    BPX-601 GoCAR-T Targets Solid Tumors Expressing PSCA Product Profile Summary & Program Update Unmet Need Unmet need in mCRPC remains, particularly in § Attractive first-in-class solid tumor CAR-T opportunity; first-in- patients who have progressed after androgen human experience with iMC deprivation

  14. Slide 14: BPX-601: GoCAR-T Increased Immunomodulatory Cytokines

    BPX-601: GoCAR-T Increased Immunomodulatory Cytokines Infusion of BPX-601 and activation with rimiducid increased immunomodulatory cytokines § Increases in Th1 and Th2 cytokines were observed with: Administration of § BPX-601 GoCAR-T cells § GoCAR-T activation with rimiducid Shaw et al, ASCO GI 2020

  15. Slide 15: BPX-601: GoCAR-T Tumor Infiltration

    BPX-601: GoCAR-T Tumor Infiltration On-treatment biopsies taken from metastatic lesions show BPX-601 tumor infiltration BPX-601 Infiltration 5 0 0 Analysis of tumor § metastases from 4 0 0 patients showed: 212 T u m o r 3 0 0 Infiltration of BPX-601 § S t r o m a GoCAR-T cells 161 A d j. N o r m a l

  16. Slide 16: BPX-601: Modulation of Tumor Microenvironment

    BPX-601: Modulation of Tumor Microenvironment Changes in gene expression consistent with productive T cell immune responses § Upregulation of T/CAR-T Differentially Expressed Genes in Tumor Metastases After BPX-601 + Rim cell associated genes (Cohort 5B, n=3) including: GZMB – Target cell killing §

  17. Slide 17: Rationale for Rimiducid Dose Escalation

    Rationale for Rimiducid Dose Escalation In non-clinical models, increasing exposure to rimiducid leads to… Increased Enhanced Improved GoCAR-T Cell Persistence Cytokine Production Anti-Tumor Efficacy OE19 Tumor Bioluminescence T cell Bioluminescence Serum IFN-γ Levels Day 37 post T cell transplantaK

  18. Slide 18: BPX-601: BP-012 Phase 1/2 Study

    BPX-601: BP-012 Phase 1/2 Study Dose escalation in relapsed metastatic castration-resistant prostate cancer (mCRPC) Planned mCRPC Phase 1 – 3+3 Design* mCRPC Dose Escalation Rationale • DL1 established safety in mCRPC at previously cleared Dose Level 1 Dose Level 2 Dose Levels 3+ dose/schedule in pa

  19. Slide 19: BPX-603 HER-2 Dual-Switch GoCAR-T

    BPX-603 HER-2 Dual-Switch GoCAR-T 19

  20. Slide 20: BPX-603 Dual Switch GoCAR-T Targeting HER2

    BPX-603 Dual Switch GoCAR-T Targeting HER2 Unmet Need Product Profile Summary & Program Update 5-year OS § HER2 is a validated tumor antigen expressed on numerous solid 1 + Indication Incidence HER2 1 (Stage IV) tumors with high unmet need 3 Gastric 28,000 10-30% <20% § BPX-603 designed to potential

  21. Slide 21: Historical HER2 Studies: Modest Clinical Outcomes

    Historical HER2 Studies: Modest Clinical Outcomes Study Properties Morgan, 2010 Ahmed, 2015 Feng, 2017 Ahmed, 2017 Hegde, 2019 Construct 4D5-28-BB-z FRP5-28-z Her2-BB-z FRP5-28-z FRP5-28-z Indication(s) Metastatic colon Sarcomas CCA and PCa GBM Sarcomas Patient number 1 19 11 17 10 HER2 expression ≥

  22. Slide 22: BPX-603: Compelling Preclinical Evidence

    BPX-603: Compelling Preclinical Evidence iMC co-activation enhances cell proliferation Moderate affinity scFv enhances relative to current CAR-T standards anti-tumor effect relative to low affinity FRP5 Tumor growth T cell bioluminescence 10000000 100 10 1000000 BPX-603 + Rim NT 1 FRP5 + Rim 100000

  23. Slide 23: BPX-603 Phase 1/2 Trial Design

    BPX-603 Phase 1/2 Trial Design Two-Part Safety/Activity Study of HER2-Targeted Dual Switch GoCAR-T Cells in Previously Treated HER2+ Solid Tumors Phase 1: 3+3 Dose Escalation Phase 2: Multi-Arm Dose Expansion in Select Tumor Types Cohort 1: Gastric • Expansion cohorts 10 patients each Locally advanc

  24. Slide 24: Expanding the Use of CaspaCIDe Through Licensing

    Expanding the Use of CaspaCIDe Through Licensing 24

  25. Slide 25: Expanding the Use of CaspaCIDe Through Licensing

    Expanding the Use of CaspaCIDe Through Licensing Summary New Licensing Agreements in 2021 § CaspaCIDe is the most clinically-validated safety switch, offering § The University of Texas the potential to improve the benefit/risk of cell therapies MD Anderson Cancer Center § Bellicum has established op

  26. Slide 26: Summary

    Summary > Bellicum 2

  27. Slide 27: Anticipated Key Program Goals & Milestones

    Anticipated Key Program Goals & Milestones Product Candidate Goals & Milestones Planned Timing BPX-601 Phase 1 data update in mCRPC 2022 PSCA GoCAR-T BPX-603 Phase 1 data update 2022 HER2 GoCAR-T (Dual-Switch) 27

  28. Slide 28: Investment Summary

    Investment Summary Building a next generation cell therapy pipeline around the GoCAR platform GoCAR Platform Differentiated co-activation domain (MyD88/CD40) and switch technology drive greater proliferation, persistence, power, and performance BPX-601 BPX-603 • Autologous GoCAR-T targeting PSCA • A

Bellicum Pharmaceuticals — Investor Presentation (December 2021) on 6ix